Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on November 6, 2024, by Citius Pharmaceuticals, Inc., a Nevada corporation. The filing addresses the status of the Company's listing on The Nasdaq Capital Market following a delisting determination due to non-compliance with the minimum bid price requirement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
- Non-Compliance History: The Company failed to maintain the required $1.00 minimum bid price for 30 consecutive business days, initially notified in September 2023.
- Extensions and Delisting: After receiving an extension to September 9, 2024, the Company failed to regain compliance and received a delisting determination letter on September 10, 2024.
- Hearing Outcome: A hearing before the Nasdaq Hearings Panel was held on October 29, 2024. On November 6, 2024, the Panel granted the Company's request to continue its listing.
- Compliance Deadline: The Company must regain compliance with the Bid Price Rule on or before December 3, 2024.
Outlook, Risks, and Management Commentary
Management notes that there can be no assurance the Company will ultimately meet all applicable requirements for continued listing. The Company is required to provide prompt notification of any significant events during the compliance period that may affect its status. The filing includes standard forward-looking statements disclaiming guarantees regarding future compliance or stock price performance.
Investor Verification Checklist
- Verify the current trading price of CTXR common stock to assess proximity to the $1.00 minimum bid price requirement.
- Monitor the Company's ability to meet the December 3, 2024, compliance deadline.
- Review the Company's Annual Report on Form 10-K for the year ended September 30, 2023, for detailed risk factors.
- Watch for subsequent filings regarding any significant events that could impact listing status before the deadline.